Long Term Treatment of Patients With Major Depressive Disorder With MK0869 (0869-065)(COMPLETED)

Phase 3

Completed

• Conditions: Major Depressive Disorder

• Registration Number: NCT00048594
• Lead Sponsor: Merck Sharp & Dohme LLC

Brief Summary

A clinical study to determine the efficacy and safety of an investigational medication (MK0869) in the treatment of depression.

Detailed Description

The duration of treatment is 20 months.

Study Timeline

• Study Start: 2002-01-03
• Study First Submitted: 2002-11-04
• Study First Submitted QC: 2002-11-04
• Study First Posted: 2002-11-05
• Primary Completion: 2003-12-18
• Study Completion: 2003-12-22
• Status Verified: 2017-05
• Last Update Submitted: 2017-05-02
• Last Update Posted: 2017-05-05

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 800

Inclusion Criteria

Not provided

Read More

Exclusion Criteria

Not provided

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Total HAMD-17 score </= 10 after 10 weeks of treatment, time to relapse of depression over 6-10 months	after 10 weeks of treatment and over 6-10 months

Secondary Outcome Measures

Name	Time	Method
CGI-S score change from Week 10 at Month 6; HAMD-17 total score change from Week 10 at Month 6; an HAMA total score change from week 10 at Month 6.	Week 10 at Month 6